March 2, 2026 Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Announces Revisions to Its Financial ForecastsSumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2026, which were announced on October 31, 2025, as summarized below, taking the Group's recent business performance trends into consideration.
Revisions to Its Financial Forecasts for the Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)
(Millions of yen)
Revenue
Core operating profit
Operating profit
Net profit attributable to owners of the
parent
Basic earnings per share
Previous Forecasts (A)
429,000
97,000
98,000
92,000
¥231.57
Revised Forecasts (B)
449,000
107,000
108,000
102,000
¥256.74
Variance in amount (B－A)
20,000
10,000
10,000
10,000
-
Variance in percent (%)
4.7
10.3
10.2
10.9
-
[Reference] Previous year
(Year ended March 31, 2025)
398,832
43,153
28,804
23,634
¥59.49
Note: Core operating profit is calculated by deducting from operating profit any gains and losses resulting from nonrecurring factors, including changes in fair value of contingent consideration, impairment losses, and business structure improvement expenses.
Reasons for the revisions
In the revised forecasts announced today, the Company has changed the full-year foreign exchange assumption (average exchange rate for the period) from 145.0 JPY to 150.0 JPY against 1 USD, as compared with the previous forecast.
Revenue has been revised upward by 20.0 billion JPY to 449.0 billion JPY, reflecting higher-than
-expected sales of products such as GEMTESA® (therapeutic agent for overactive bladder) in the North America segment, as well as the positive impact of the weaker yen.
Core operating profit has been revised upward by 10.0 billion JPY to 107.0 billion JPY. In addition to the increase in gross profit resulting from higher revenue, selling, general and administrative expenses and R&D expenses are now expected to be slightly lower than the previous forecast, excluding the impact of yen depreciation.
Driven by the increase in core operating profit, operating profit has been revised upward by
10.0 billion JPY to 108.0 billion JPY and profit attributable to owners of the parent has been revised upward by 10.0 billion JPY to 102.0 billion JPY, compared with the previous forecast.
Disclaimer Regarding Forward-looking Statements
The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.
Contact:
Corporate Communications, Corporate Governance Sumitomo Pharma Co., Ltd.
E-mail: prir@sumitomo-pharma.co.jp.